maltotriose undecabenzoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: maltotriose undecabenzoate
• 英文别名: maltotriose perbenzoate；Bz(-2)[Bz(-3)][Bz(-4)][Bz(-6)]Glc(a1-4)[Bz(-2)][Bz(-3)][Bz(-6)]Glc(a1-4)[Bz(-2)][Bz(-3)][Bz(-6)]Glc-O-Bz；[(2R,3R,4S,5R,6R)-4,5-dibenzoyloxy-6-[(2R,3R,4S,5R)-4,5,6-tribenzoyloxy-2-(benzoyloxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5R,6R)-3,4,5-tribenzoyloxy-6-(benzoyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl benzoate
• 化学式: C₉₅H₇₆O₂₇
• 分子量: 1649.63
• InChiKey: UOOLEFBTTKOMBF-UKUSSFMUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  17.1
• 重原子数：
  122
• 可旋转键数：
  40
• 环数：
  14.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  335
• 氢给体数：
  0
• 氢受体数：
  27

反应信息

• 作为反应物：
  描述：

  maltotriose undecabenzoate 在 氢溴酸 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以100%的产率得到deca-O-benzoyl-α-maltotriosyl bromide
  参考文献：
  名称：

  [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS

  摘要：

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。

  公开号：

  WO2009049370A1
• 作为产物：
  描述：

  maltotriose 、 苯甲酰氯 在 4-二甲氨基吡啶 作用下， 以 吡啶 为溶剂， 以85%的产率得到maltotriose undecabenzoate
  参考文献：
  名称：

  Ferro, Vito; Meldal Morten; Bock, Klaus, Journal of the Chemical Society. Perkin transactions I, 1994, # 15, p. 2169 - 2176

  摘要：

  DOI：

文献信息

• [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS
  申请人：PROGEN PHARMACEUTICALS LTD

  公开号：WO2009049370A1

  公开（公告）日：2009-04-23

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。
• Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis
  作者：Vito Ferro、Ligong Liu、Ken D. Johnstone、Norbert Wimmer、Tomislav Karoli、Paul Handley、Jessica Rowley、Keith Dredge、Cai Ping Li、Edward Hammond、Kat Davis、Laura Sarimaa、Job Harenberg、Ian Bytheway

  DOI：10.1021/jm201708h

  日期：2012.4.26

  Increasing the aglycone lipophilicity of a series of polysulfated oligosaccharide glycoside heparan sulfate (HS) mimetics via attachment of a steroid or long chain alkyl group resulted in compounds with significantly improved in vitro and ex vivo antiangiogenic activity. The compounds potently inhibited heparanase and HS-binding angiogenic growth factors and displayed improved antitumor and antimetastatic activity in vivo compared with the earlier series. Preliminary pharmacokinetic analyses also revealed significant increases in half-life following iv dosing, ultimately supporting less frequent dosing regimens in preclinical tumor models compared with other HS mimetics. The compounds also displayed only mild anticoagulant activity, a common side effect usually associated with HS mimetics. These efforts led to the identification of 3 beta-cholestanyl 2,3,4,6-tetra-O-sulfo-alpha-D-glucopyranosyl- (1 -> 4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1 -> 4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1 -> 4)-2,3,6-tri-O-sulfo-beta-D-glucopyranoside, tridecasodium salt (PG545, 18) as a clinical candidate. Compound 18 was recently evaluated in a phase I clinical trial in cancer patients.
• Ferro, Vito; Meldal Morten; Bock, Klaus, Journal of the Chemical Society. Perkin transactions I, 1994, # 15, p. 2169 - 2176
  作者：Ferro, Vito、Meldal Morten、Bock, Klaus

  DOI：——

  日期：——